Boston Scientific (NYSE:BSX – Get Rating) and PetVivo (OTCMKTS:PETV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Boston Scientific and PetVivo, as reported by MarketBeat.com.
Get Boston Scientific alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Boston Scientific | 0 | 1 | 10 | 1 | 3.00 |
| PetVivo | 0 | 0 | 1 | 0 | 3.00 |
Boston Scientific currently has a consensus price target of $46.55, indicating a potential upside of 13.11%. PetVivo has a consensus price target of $7.00, indicating a potential upside of 178.88%. Given PetVivo's higher possible upside, analysts plainly believe PetVivo is more favorable than Boston Scientific.
Profitability
This table compares Boston Scientific and PetVivo's net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Boston Scientific | 7.16% | 14.58% | 7.60% |
| PetVivo | -3,817.65% | -99.68% | -82.24% |
Insider & Institutional Ownership
90.5% of Boston Scientific shares are held by institutional investors. Comparatively, 13.7% of PetVivo shares are held by institutional investors. 0.7% of Boston Scientific shares are held by company insiders. Comparatively, 35.3% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Boston Scientific and PetVivo's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Boston Scientific | $11.89 billion | 4.95 | $1.04 billion | $0.58 | 70.95 |
| PetVivo | $120,000.00 | 209.96 | -$5.01 million | ($0.75) | -3.35 |
Boston Scientific has higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Boston Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Summary
Boston Scientific beats PetVivo on 10 of the 14 factors compared between the two stocks.
About Boston Scientific
(Get Rating)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
About PetVivo
(Get Rating)
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.